Valuation : Evolus, Inc.

Market Cap 587M 505M 474M 433M 815M 56.06B 818M 5.62B 2.19B 28.3B 2.2B 2.15B 93.83B P/E 2026 *
-18.3x
P/E 2027 * -56.7x
Enterprise Value 708M 610M 572M 522M 983M 67.62B 986M 6.78B 2.65B 34.13B 2.66B 2.6B 113B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.82x
Free-Float
81.64%
Yield 2026 *
-
Yield 2027 * -
1 week+6.17%
Current month+49.39%
1 month+39.22%
3 months+35.09%
6 months+109.06%
Current year+38.86%
1 week 6.98
Extreme 6.98
7.75
1 month 4.96
Extreme 4.963
7.75
3 years 3.36
Extreme 3.36
16.1
5 years 3.36
Extreme 3.36
16.1
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+6.17%+20.13%-16.38% 587M
-0.13%-6.44%+60.34%+112.06% 1,047B
+0.85%-0.81%+51.29%+63.13% 646B
-1.03%-3.58%+21.43%+73.10% 451B
-1.46%-4.50%+37.80%+37.41% 355B
-0.72%-2.89%+22.32%+36.62% 291B
-1.19%-2.21%+1.53%+10.79% 252B
-1.05%-1.57%+50.30%+66.55% 234B
+0.08%-1.78%-17.64%-54.36% 203B
-2.14%-0.30%+28.95%+86.27% 181B
Average -0.75%-2.68%+27.64%+41.52% 406.59B
Weighted average by Cap. -0.46%-3.46%+38.17%+64.99%

Financials

2026 *2027 *
Net sales 334M 288M 270M 247M 465M 31.96B 466M 3.21B 1.25B 16.13B 1.26B 1.23B 53.5B 391M 337M 316M 289M 544M 37.41B 546M 3.75B 1.46B 18.88B 1.47B 1.44B 62.62B
Net income -31.55M -27.18M -25.49M -23.27M -43.83M -3.02B -43.97M -302M -118M -1.52B -118M -116M -5.05B -9.69M -8.35M -7.83M -7.15M -13.46M -926M -13.51M -92.88M -36.24M -467M -36.38M -35.59M -1.55B
Net Debt 121M 104M 97.76M 89.24M 168M 11.56B 169M 1.16B 453M 5.84B 454M 444M 19.36B 126M 109M 102M 92.93M 175M 12.04B 176M 1.21B 471M 6.08B 473M 463M 20.16B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
-
Date Price Change
28/08/26 €7.568 +0.42%
27/08/26 €7.536 -0.53%
26/08/26 €7.576 -0.76%
25/08/26 €7.634 +2.25%
24/08/26 €7.466 +4.74%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.880USD
Average target price
15.00USD
Spread / Average Target
+68.92%

Quarterly revenue - Rate of surprise